Redefining insulin therapy in type 2 diabetes mellitus

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus is a progressive condition marked by insulin resistance and declining insulin secretion, worsened by hyperglycemia.
• Chronic hyperglycemia (glucotoxicity) accelerates beta-cell dysfunction in type 2 diabetes.
• Current treatments often fail to prevent disease progression.

Purpose of the Study:

• To evaluate the potential benefits of early insulin introduction in managing type 2 diabetes.
• To explore insulin's role in preserving beta-cell function and improving insulin action.
• To assess the feasibility of early basal insulin supplementation after oral agent failure.

Main Methods:

• Review of mounting evidence and hypothesis-generating data on early insulin therapy.
• Extrapolation of clinical practice tools from the Treat-to-Target Trial.
• Analysis of basal insulin glargine's efficacy and safety compared to NPH insulin.

Main Results:

• Early basal insulin supplementation may preserve beta-cell integrity and delay cell loss.
• This approach has the potential for more sustained glycemic control.
• Basal insulin glargine, with a structured titration algorithm, achieved glycemic targets with less nocturnal hypoglycemia than NPH insulin.

Conclusions:

• Earlier introduction of insulin therapy is a promising strategy for type 2 diabetes management.
• Basal insulin glargine offers a viable option for achieving stringent glycemic control.
• Long-term controlled studies are essential to confirm this treatment paradigm.